Insights+ COVID-19 Deals (Part III): Biopharma and Govt. Institutions

The emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and kits. This article covers the last six months of deal data provided by Chris Dokomajilar of DealForma. During the last six months (up to Jun 25, 2020) around 403 deals were made, the breakup of deals are as follows:

  •     107 were done between biopharma companies,
  •     88 between biopharma and govt. organizations/foundations/consortium
  •     61 between biopharma and universities
  •     60 between biopharma/medical devices/diagnostics/digital health companies
  •     33 among universities and academic institutions

We have compiled a list of 20 deals among biopharma companies and government organizations based on transaction values.

1. Barda Contract Service Deal with AstraZeneca to Develop Azd1222 Recombinant Adenovirus Vaccine (formerly ChAdOx1 nCoV-19)

Date: May 21, 2020

Deal Value: $1.2B

BARDA signed a contract service deal with AstraZeneca to develop and manufacture the AZD1222 recombinant adenovirus vaccine (formerly ChAdOx1 nCoV-19) for COVID-19. AZD1222 was developed by Oxford University’s Jenner Institute, working with the Oxford Vaccine Group. AstraZeneca to manufacture 400 million doses and secure total manufacturing capacity for 1 billion doses by September 2020. AstraZeneca to receive $1B from BARDA to support P-III development.

2. Johnson & Johnson Research Partnership with BARDA

Date: Feb 11, 2020

Deal Value: $1B

Johnson & Johnson (J&J) signed a research partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a vaccine using Janssen’s AdVac and PER.C6 technologies for the treatment of coronavirus disease (COVID-19). Additionally, J&J to upscale the vaccine manufacturing facility. Financials were not disclosed but BARDA to fund the P-I study to accelerate the development of a vaccine candidate.   On Mar 30, 2020, J&J selected the lead vaccine candidate for coronavirus disease and expected to initiate the human study by Sep 2020. Johnson & Johnson intends to launch the Vaccine in early 2021 with a global supply of over one billion. BARDA and J&J to co-fund the vaccine development program more than $1B, plus an additional undisclosed commitment from BARDA.

3. BARDA Contract Service Deal with Phlow

Date: May 19, 2020

Deal Value: $0.81B

BARDA signed a contract service deal with Phlow to manufacture up to 1.6M doses of five essential generic medicines used in the prevention of COVID-19, including medicines for sedation, pain management, and certain antibiotics. Phlow to receive $354M upfront with an option payment of $458M from BARDA.

4. Emergent BioSolutions Contract Service Deal with Health & Human Services (HHS)

Date: Jun 01, 2020

Deal Value: $0.68M

Emergent BioSolutions signed a contract service deal with Health & Human Services to manufacture COVID-19 vaccines. Emergent BioSolutions to receive $542.7M. Additionally, HHS to provide $85.5M for the expansion of product fill/finish capacity.

5. BARDA Grant to Moderna for its mRNA-1273 SARS-CoV-2 Vaccine

Date: Apr 16, 2020

Deal Value: $0.48B

Moderna received $483M as a grant from the Biomedical Advanced Research and Development Authority (BARDA) to develop Moderna’s mRNA vaccine candidate, mRNA-1273 for SARS-CoV-2.

6. Government of Canada Grant to AbCellera to Discover Antibodies for the Treatment of COVID-19

Date: May 03, 2020

Deal Value: $0.175B

AbCellera received $175.6M as a grant from the Government of Canada to discover antibodies for the prevention of COVID-19 and to build technology and manufacturing infrastructure for antibody therapies.

7. SiO2 Materials Science Contract Service Deal with BARDA

Date: Jun 08, 2020

Deal Value: $0.143B

SiO2 Materials Science signed a contract service deal with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to accelerates the production of SiO2 Materials’ primary packaging platform for storing vaccines and therapeutics of SARS-CoV-2. SiO2 to receive $143M for the contract.

8. HHS-DOD Defense Production Act (DPA) Contract Service Deal with ApiJect for Population-scale Emergency Drug Injection Solution

Date: May 12, 2020

Deal Value: $0.138B

The U.S. Department of Health and Human Services and Department of Defense signed a contract service deal with ApiJect under the Defense Production Act (DPA) to accelerate the development of high-speed population-scale emergency drug injection solutions with prefilled syringes through its subsidiary RAPID USA under its emergency program Project Jumpstart. ApiJect to receive $138M for the contract.

9. Novavax Contract Service Deal with the US Department of Defense

Date: Jun 04, 2020

Deal Value: $0.06B

Novavax signed a contract service deal with the US Department of Defense to manufacture the antigen component and Matrix-M adjuvant component of the vaccine, NVX-CoV2373 for 10 million doses of vaccine for the prevention of COVID-19. Novavax to receive $60M from DoD.

10. BARDA Contract Service Deal with Emergent Biosolutions to Develop Plasma-Based Therapeutics for COVID-19

Date: Apr 09, 2020

Deal Value: $0.036B

BARDA signed a contract service deal with Emergent Biosolutions to develop plasma-based therapeutics for COVID-19. Emergent’s Center for Innovation in Advanced Development and Manufacturing to conduct the research and to receive $14.5M from BARDA and is eligible to receive up to $22M for additional development.

11. BARDA Contract Service Deal with Genentech to Develop Actemra for COVID-19

Date: Apr 06, 2020

Deal Value: $0.025B

BARDA signed a contract service deal with Genentech to develop Actemra for the treatment of COVID-19. Genentech to receive $25M from BARDA to support the development.

12. BARDA Grant to SAB Biotherapeutics

Date: Apr 02, 2020

Deal Value: $0.016B

SAB Biotherapeutics along with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) to receive $7.2M as a grant from BARDA to complete manufacturing and preclinical studies, with an option to conduct a P-I study of SAB-185 for the treatment of COVID-19.  On Apr 16, 2020, BARDA expanded the contract, and SAB Biotherapeutics to receive up to $9.4M.

13. BARDA Grant to Emergent to Develop COVID-HIG

Date: Apr 02, 2020

Deal Value: $0.014B

Emergent BioSolutions to receive $14.5M as a grant from BARDA to develop COVID-HIG, a human plasma-derived therapy candidate for the prevention of SARS-CoV-2.

14. DOD Contract Service Deal with Ology Bioservices for COVID-19

Date: Mar 23, 2020

Deal Value: $0.014M

The Department of Defense (DOD) signed a contract service deal with Ology Bioservices for the development and manufacturing of monoclonal antibodies for the prevention of Coronavirus disease, COVID-19. Ology to receive $14M. 

15. Ology Bioservices and Inovio Contract Service Deal with Department of Defense

Date: Mar 24, 2020

Deal Value: $0.011B

Ology Bioservices and Inovio signed a contract service deal with the Department of Defense to manufacture Inovio’s DNA vaccine (INO-4800) for prevention of COVID-19 virus infection to deliver the vaccine rapidly and efficiently to the Department of Defense. Ology Bioservices to receive $11.9M from the Department of Defense.

16. Government of Quebec Grant to Medicago

Date: Mar 21, 2020

Deal Value: $0.007B

Medicago to receive $7M as a grant from the Government of Quebec to develop a vaccine for the prevention of COVID-19. 

17. Horizon 2020 Grant to Cobra Biologics

Date: Mar 30, 2020

Deal Value: $0.003B

Cobra Biologics and Karolinska Institutet to receive $3.3M as a grant from Horizon 2020 to develop phase I clinical trial testing of a DNA vaccine for the prevention of COVID-19. 

18. NIH Grant to CytoAgents

Date:May 13 , 2020

Deal Value: $0.001B

CytoAgents to receive a $1.6M Phase-2 SBIR grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to develop GP1681 for the prevention of Influenza and COVID-19. 

19. Israel Innovation Authority (IIA) Grant to Enlivex

Date: Apr 13 , 2020

Deal Value: $0.001B

Enlivex to receive $1.5M as a grant from Israel Innovation Authority (IIA) to develop Allocetra for the prevention of COVID-19 and organ dysfunction associated with sepsis.

20. NIH Grant to Adjuvance

Date: May 19, 2020

Deal Value: $0.001B

Adjuvance to receive $1.47M as a grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to evaluate TQL1055 for the prevention of COVID-19.

Related Post : Insights+ COVID-19 Deals (Part I): Biopharma Drug Development

Related Post: Insights+ COVID-19 Deals (Part II): Biopharma Vaccine Development